首页 | 本学科首页   官方微博 | 高级检索  
     

阿加曲班联合阿司匹林治疗穿支动脉病变型进展性脑梗死的临床研究
引用本文:孙凯,王栩,王漫,粟虹燚,武红,解衍龙,张萍. 阿加曲班联合阿司匹林治疗穿支动脉病变型进展性脑梗死的临床研究[J]. 现代药物与临床, 2022, 37(3): 576-581. DOI: 10.7501/j.issn.1674-5515.2022.03.024
作者姓名:孙凯  王栩  王漫  粟虹燚  武红  解衍龙  张萍
作者单位:天津中医药大学,天津 301617,天津市中医药研究院附属医院,天津 300120
摘    要:目的 观察阿加曲班联合阿司匹林治疗穿支动脉病变型进展性脑梗死的临床疗效.方法 选取2018年1月—2020年12月天津市中医药研究院附属医院针灸病房收治的120例穿支动脉病变型进展性脑梗死患者,根据随机数字表法将患者分为对照组和治疗组,每组各60例,剔除脱落病例(n=9)后剩余对照组56例,治疗组55例.对照组口服阿司...

关 键 词:阿加曲班注射液  阿司匹林肠溶片  进展性脑梗死  穿支动脉病变  美国国立卫生研究院卒中量表评分  血浆脂蛋白磷脂酶A2  D-二聚体
收稿时间:2021-12-17

Clinical study of argatroban combined with aspirin in treatment of progressive cerebral infarction with perforator artery lesions
SUN Kai,WANG Xu,WANG Man,SU Hong-yi,WU Hong,XIE Yan-long,ZHANG Ping. Clinical study of argatroban combined with aspirin in treatment of progressive cerebral infarction with perforator artery lesions[J]. Drugs & Clinic, 2022, 37(3): 576-581. DOI: 10.7501/j.issn.1674-5515.2022.03.024
Authors:SUN Kai  WANG Xu  WANG Man  SU Hong-yi  WU Hong  XIE Yan-long  ZHANG Ping
Affiliation:Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China
Abstract:Objective To observe the clinical efficacy of argatroban combined with aspirin in treatment of progressive cerebral infarction caused by perforator artery lesions. Methods A total of 120 patients with progressive cerebral infarction with perforating artery lesions treated in the acupuncture ward of Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital from January 2018 to December 2020 were selected. According to the random number table method, the patients were divided into control group and treatment group, with 60 cases in each group. After removing the detached cases (n=9), there were 56 cases in the control group and 55 cases in the treatment group. Patients in the control group were po administered with Aspirin Enteric-coated Tablets, 100 mg/time, once daily. Patients in the treatment group were iv administered with Argatroban Injection on the basis of the control group, 60 mg/d was diluted with appropriate infusion and continued intravenous infusion for 48 h. Then the dosage was reduced to 20 mg/d, twice daily, and intravenous infusion was given for 12 d. Both groups were treated for 14 d. The clinical efficacy of the two groups were observed, and the scores of national Institutes of Health Stroke Scale (NIHSS), Barthel index, plasma lipoprotein phospholipase A2 (LP-PLA2), D-dimer and activated partial thrombin time (APTT) were compared between the two groups. Results After treatment, the total effective rate of treatment group was 81.82%, significantly higher than that of control group 62.50% (P < 0.05). After treatment, NIHSS score was significantly decreased, but Barthel index was significantly increased in both groups (P < 0.05). NIHSS score in the treatment group was significantly lower than that in the control group, but Barthel index was significantly higher than that in the control group, with statistically significant differences between the two groups (P < 0.05). After treatment, LP-PLA2 and D-Dimer in the two groups were significantly decreased, while APTT was significantly increased (P < 0.05). LP-PLA2 and D-Dimer in the treatment group were significantly lower than those in the control group, but APTT was significantly higher than those in the control group (P < 0.05). Conclusion Agaltreban combined with aspirin has good efficacy in treatment of progressive cerebral infarction with perforator artery lesions, and can improve patients'' neurological function and blood hypercoagulability, and improve their living ability with high safety.
Keywords:Argatroban Injection  Aspirin Enteric-coated Tablets  progressive cerebral infarction  perforator artery lesions  NIHSS score  LP-PLA2  D-Dimer
本文献已被 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号